Tirzepatide, a groundbreaking drug, represents a significant advance in the approach of type 2 diabetes and, more recently, obesity. This dual agonist acts upon two crucial receptors: glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Unlike traditional medications for diabetes, Tirzepatide encourages not only production of i